JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

Lancet Oncol. 2007 Jul;8(7):658-60. doi: 10.1016/S1470-2045(07)70206-1.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chromosome Aberrations
  • Chronic Disease
  • DNA Mutational Analysis
  • Genes, abl / genetics
  • Humans
  • Imatinib Mesylate
  • Janus Kinase 2 / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Piperazines / therapeutic use
  • Polymerase Chain Reaction
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • JAK2 protein, human
  • Janus Kinase 2